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Leveraging unique structural characteristics of WNK
kinases to achieve therapeutic inhibition
Jinwei Zhang,1 Xianming Deng,2 Kristopher T. KahleAQ1 3*
The with-no-lysine (K) WNK kinases are master regulators of the Na+-(K+)-Cl− cotransporters, including the renal-
specific NCC and NKCC2 cotransporters. The discovery of WNK463, an orally bioavailable pan-WNK kinase inhibitor
that exploits unique structural properties of the WNK catalytic domain to achieve high affinity and kinase selectivity,
illustrates a strategy of leveraging distinct kinase features to develop specific inhibitors and validates the genetic pre-
dictions of the in vivo pharmacology of WNK inhibition.
Protein kinases are pathogenically mutated in
multiple human diseases, including cancer,
neuropsychiatric disorders, inflammatory
conditions, infectious diseases, and cardio-
vascular diseases (1). About one-third of all
protein targets under investigation in the phar-
maceutical industry are kinases; more than 30
kinase inhibitors are approved for clinical use;
and dozens of other kinase inhibitors are ac-
tively under investigation in clinical trials (2).
Despite this, the available armamentarium of
clinically used kinase inhibitors covers less
than 15% of the kinome, and these are used
overwhelmingly for oncological conditions
(2). Compared to cancer inwhich lack of treat-
ment is often lethal, the bar is set much higher
for kinase drug discovery in chronic condi-
tions, because exquisite target selectivity and
aminimumof side effects are required to com-
pete with existing therapies (1).
Kinases of the WNK (with-no-lysine) family
are different from other kinases, because of
the unusual placement of the catalytic lysine 
residue in WNK isoforms (Lys233 of WNK1) 
AQ2 compared to the active site lysine in all other 
protein kinases (3). This peculiarity could theo-
retically be exploited to create WNK-specific 
ATP-competitive kinase inhibitors. Indeed, 
Yamada et al. exploited these unique structural 
features to conduct a high-throughput screen
for inhibitors of WNK1 catalytic activity (4). 
They discovered the first orally bioavailable 
pan-WNK kinase inhibitor, WNK463, which 
exhibits both low nanomolar affinity and high 
AQ3 kinase selectivity. By solving the x-ray crystal
structure of WNK463 with the kinase-dead
mutant WNK1 S382A at 1.65 Å resolution,
Yamada et al. showed that WNK463 contacts
the hinge region of the ATP binding site by
burrowing through a narrow tunnel to the
back pocket of WNK1, which occurs because
of the nonstandard placement of the catalytic
Lys233 in the glycine-rich loop ( F1Fig. 1A).
Genetic inhibition of WNK kinases pro-
motes blood pressure reduction by stimulating 
both diuresis and vasodilation; therefore, these 
kinases have garnered much attention as po-
tential targets for the development of anti-
hypertensive agents. Mutations in WNK1 
(encoded by PRKWNK1) and WNK4 (encoded 
by PRKWNK4) cause an autosomal dominant 
form of hypertension that is also associated with 
hyperkalemia termed Gordon’s syndrome o r 
pseudohypoaldosteronism type II (PHAII; 
OMIM #614496) (5). The WNK kinases regu-
late blood pressure and electrolyte homeostasis 
by phosphorylating and activating two related 
Ste20-type kinases termed STE20/SPS1-related 
proline/alanine-rich kinase (SPAK) and oxi-
dative stress-responsive kinase 1 (OSR1), col-
lectively referred to as SPAK/OSR1. Activated 
SPAK/OSR1 phosphorylate and stimulate the 
activities of two related cation-Cl− cotransport-
ers in the kidney in the aldosterone-sensitive 
part of the nephron, the Na+-Cl− cotransporter 
NCC and the Na+-K+-2Cl− cotransporter 
NKCC2 (Fig. 1B).WNKs also regulate NKCC1  
and KCC2, cation-Cl− cotransporters that are 
critical for establishing Cl− homeostasis in the 
nervous system and are implicated in multiple 
diseases characterized by neuronal excitability 
due to GABA disinhibition (6). These actions 
of theWNKsmake them attractive candidates  
for the development of inhibitors to treat these 
diseases as well.
Yamada et al. testedWNK463 ina rathyper-
tensionmodel (4). In spontaneouslyhypertensive
rats, orally administeredWNK463 significant-
ly decreased blood pressure, increased urine
output, and reduced the phosphorylation of
SPAK and OSR1. This proof-of-biology study
is important, because it establishes the impor-
tance of the WNK kinase catalytic domain in
blood pressure and electrolyte homeostasis and
confirms predictions made by human and ro-
dent genetics about the in vivopharmacology of
WNKkinase inhibition (7).Moreover,WNK463
will be an important research reagent that will
help illuminate CCC regulation and the role of
The development of WNK463 as a po-
tential therapeuticwas discontinueddue to other
unspecified effects beyond those reported in
the cardiovascular and renal systems when
administered to the rats at higher concentra-
tions (4). This is perhaps not surprising, be-
cause the WNK kinases (including WNK2
and WNK3, kinases that are not mutated in
PHAII) are present throughout the body, al-
though some isoforms exhibit restricted dis-
tribution. For example, the HSN2 isoform of
WNK1 is almost exclusively detected in the
nervous system, including the spinal cord dorsal
horn, and inactivating HSN2 mutations cause
hereditary sensory and autonomic neuropa-
thy type IIA (HSANII; OMIM #201300) (8).
Pan-WNK inhibitionmight, therefore, affect
physiological process beyond those of blood
pressure and electrolyte homeostasis.
With regard to alternative means to inhibit
theWNKpathway, where to go fromhere? The
WNKsubstrates SPAKandOSR1play a critical
role in controlling blood pressure, and SPAK-
deficient mice have markedly reduced blood
pressure yet are otherwise healthy (9). AQ5Genome-
wide association studies of essential hyper-
tension showa strong associationwith common
variants of SPAK. The strategy of targeting the
ATPbinding site of SPAK/OSR1 raises concern
regarding the ability to develop sufficiently se-
lective inhibitors that do not suppress other
kinases. The development of Closantel and
STOCK1S-14279, ATP-insensitive inhibitors,
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has introduced the possibility of devel-
oping inhibitors of the WNK pathway by
binding to constitutively active or WNK-
activated AQ6(T233E)SPAK (Fig. 1B) (10) 7.
Another approach is to target protein-
protein interaction sites. SPAK has a spe-
cific docking CCT domain that mediates
the interaction with RFxV motifs present
in WNKs, NCC, and NKCC2 (Fig. 1B)
(11). A high-resolution AQ8three-dimensional
structure of this domain complexed to the 
RFxV motif has been solved (Fig. 1A) (12). 
Screens have identified inhibitors that 
disrupt the CCT-RFxV interaction (13), 
and chemical modulation of these first-
generation inhibitors might yield com-
pounds that could be used in vivo. Because 
the CCT domain is unique to SPAK and 
OSR1, targeting this interaction site would 
not be expected to inhibit other kinases, 
which could provide sufficient specificity 
and safety for use in the treatment of a 
chronic condition, such as hypertension. 
Other strategies that antagonize tissue-
specific WNK isoforms, for example, by 
targeting the unique HSN2 isoform to treat 
neuropathic pain (14), could minimize un-
wanted side effects in other organ systems.
Major challenges remain for the devel-
opment of therapeutically effective kinase
inhibitors in non-oncological diseases, in-
cluding the identification and validation
of driver kinases in these conditions and
the discovery of drugs with adequate se-
lectivity and safety (2). Targeting kinases
that, whenmutated, disrupt human phys-
iology (even in rare inherited forms of dis-
ease) is a good strategy for the development
of personalized treatments (15). AQ9With eight
members of the WNK kinase signaling
pathway, including their upstream regula-
tors (the E3 ubiquitin ligase complexCUL3-
KLHL3) and downstream targets (SPAK
and OSR1 and cation-Cl− cotransporters),
being mutated in Mendelian forms of renal
and central nervous system pathology (7),
continuedefforts atdrugdiscovery targeting
this pathway are most certainly warranted.
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Fig. 1. Domains and sites important for regulation of and signaling through the WNK-SPAK/OSR1 pathway.
(A) Left: The structure of WNK463 bound to the kinase-dead mutant WNK1 S382A (PDB ID: 5DRB). Right: The structure of
the OSR1 CCT domain bound to the RFxV motif fromWNK4 (PDB ID: 2V3S). (B) Proteins with slashes indicate that multiple
isoforms have the same properties. For SPAK/OSR1, the residue numbering above the protein represents SPAK, and the
residue numbering below represents OSR1. Kinase X refers to a yet unidentified kinase that is regulated by WNKs and
mediates the direct phosphorylation and inhibition of Site 1 on the KCCs. STOCK1S-50699 is a small-molecule inhibitor
that blocks the interaction between SPAK/OSR1 and WNK by binding to the CCT domain (13); Closantel and STOCK1S-
14279 are SPAK (ATP-insensitive) inhibitors that bind constitutively active orWNK-sensitive (T233E)SPAKAQ11 (10); andWNK463
inhibits WNK1 catalytic activity (4).
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Abstract
One-sentence summary: Exploiting unique characteristics of the WNK-SPAK pathway may yield useful
antihypertensive medications.
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